Develops immunotherapies for cancer and infectious diseases.
Dec 2025Revenue €2.87B/yrExpenses €4.27B/yr
No trend
Figures by year
When will BioNTech be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was €2.87B and expenses €4.27B.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | €2.87B | €4.27B | −€1.40B |
| Dec 2024 | €2.75B | €4.07B | −€1.31B |
| Dec 2023 | €3.82B | €3.13B | €690M |
| Dec 2022 | €17.3B | €4.67B | €12.6B |
| Dec 2021 | €19.0B | €3.69B | €15.3B |
| Dec 2020 | €482M | €565M | −€82.4M |
| Dec 2019 | €109M | €290M | −€182M |
| Dec 2018 | €128M | €181M | −€53.9M |
| Dec 2017 | €61.6M | €123M | −€61.3M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.